Clinical Outcomes of Second-Line Amrubicin and Platinum-Based Doublet Chemotherapy in Patients with Extrapulmonary Neuroendocrine Carcinoma: A Multicenter Retrospective Study.
- DOI
- 10.3390/cancers18162664
- Published
- 2026 Aug 18
- Container
- Cancers
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/cancers18162664,
title = {Clinical Outcomes of Second-Line Amrubicin and Platinum-Based Doublet Chemotherapy in Patients with Extrapulmonary Neuroendocrine Carcinoma: A Multicenter Retrospective Study.},
author = {Yamakita N and Okumura T and Ota S and Yoneyama S and Noguchi T and Sekino Y and Nakamura M and Shinji A and Takeuchi N and Kanda S},
year = {2026},
journal = {Cancers},
doi = {10.3390/cancers18162664},
url = {https://doi.org/10.3390/cancers18162664}
}RIS
TY - JOUR TI - Clinical Outcomes of Second-Line Amrubicin and Platinum-Based Doublet Chemotherapy in Patients with Extrapulmonary Neuroendocrine Carcinoma: A Multicenter Retrospective Study. AU - Yamakita N AU - Okumura T AU - Ota S AU - Yoneyama S AU - Noguchi T AU - Sekino Y AU - Nakamura M AU - Shinji A AU - Takeuchi N AU - Kanda S PY - 2026 JO - Cancers DO - 10.3390/cancers18162664 UR - https://doi.org/10.3390/cancers18162664 ER -
APA
N, Y., T, O., S, O., S, Y., T, N., Y, S., M, N., A, S., N, T., & S, K. (2026). Clinical Outcomes of Second-Line Amrubicin and Platinum-Based Doublet Chemotherapy in Patients with Extrapulmonary Neuroendocrine Carcinoma: A Multicenter Retrospective Study.. Cancers. https://doi.org/10.3390/cancers18162664
Source records
- pubmed · retrieved 2026-09-25T19:04:52.718Z
- europe-pmc · retrieved 2026-09-25T19:04:52.868Z